title: Toxicity and exposure of an adenovirus containing human interferon alpha-2b following intracystic administration in cynomolgus monkeys.
abstract: The safety and toxicokinetics of SCH 721015, an adenovirus encoding the human interferon alpha-2b gene, and Syn3 (SCH 209702), a novel excipient, were assessed in cynomolgus monkeys administered intravesical doses of 2.5 × 10E11 or 1.25 × 10E13 particles SCH 721015 in 25 mg Syn3 or 25 mg Syn3 alone on study days 1 and 91. There was no systemic toxicity. Monkeys dosed with SCH 721015 in Syn3 were positive for SCH 721015-specific DNA in the urine for 2 to 3 days following each dose and had interferon alpha-2b protein in the urine for 1-3 days after a single dose and in fewer animals after a second dose. Intracystic administration was associated with inflammation and focal/multifocal ulceration in the urinary bladder and irritation in the ureters and urethra at necropsy. The physical trauma from catheterization and filling/emptying of the bladder was likely a contributing factor and Syn3 exacerbated the trauma. There was nearly complete resolution of these findings 2 months after the last dose. The trauma to the bladder likely contributed to low, transient systemic exposure to Syn3, SCH 721015 and human interferon protein. The results of this study support the clinical investigation of SCH 721015 in Syn3.
authors: Pfizer Inc., Pearl River, NY, USA. Robert.veneziale@pfizer.com
authors: R W
authors: RW
authors: Veneziale
authors: N S
authors: NS
authors: Kishnani
authors: J
authors: J
authors: Nelson
authors: J C
authors: JC
authors: Resendez
authors: D W
authors: DW
authors: Frank
authors: X-Y
authors: XY
authors: Cai
authors: L
authors: L
authors: Xie
authors: C
authors: C
authors: Cullen
authors: C A
authors: CA
authors: Frugone
authors: C
authors: C
authors: Rosenfeld
authors: J
authors: J
authors: Hubbell
authors: S E
authors: SE
authors: Maxwell
authors: B J
authors: BJ
authors: Sugarman
authors: B
authors: B
authors: Hutchins
authors: D
authors: D
authors: Maneval
authors: K A
authors: KA
authors: Treinen
mesh_terms: D000256:Adenoviridae / Q000235:genetics* / Q000276:immunology; D000283:Administration, Intravesical; D000818:Animals; D002793:Cholic Acids / Q000009:adverse effects*; D004187:Disaccharides / Q000009:adverse effects*; D005260:Female; D018014:Gene Transfer Techniques / Q000009:adverse effects*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000097:blood / Q000235:genetics* / Q000276:immunology / Q000652:urine; D008252:Macaca fascicularis; D008297:Male; D011994:Recombinant Proteins / Q000097:blood / Q000235:genetics / Q000276:immunology / Q000652:urine; D001743:Urinary Bladder / Q000187:drug effects
chemical_list: D002793:Cholic Acids; D004187:Disaccharides; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; C525256:Syn3 compound